Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 209.00p 206.00p 212.00p 209.00p 208.00p 209.00p 35,618 08:00:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 39.2 0.3 1.3 160.8 93.45

Ergomed Share Discussion Threads

Showing 226 to 250 of 250 messages
Chat Pages: 10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
22/2/2018
12:00
ORYX INTERNATIONAL GROWTH FUND >4%
mfhmfh
16/2/2018
15:18
solid buys coming in today
mfhmfh
07/2/2018
11:41
Octopus Investments Nominees Limited above 7%
mfhmfh
06/2/2018
09:16
Slater investments above 10%
mfhmfh
29/1/2018
15:44
Nice little proactive article below - gets blocked !! hTTp://www.proa_t_v_investors.co.uk/companies/news/190625/ergomed-update-underlines-the-potential-of-the-company-s-primevigilance-unit-190625.html
piedro
25/1/2018
16:58
Nice little proactive article below:- Ergomed’s drugs safety unit alone is worth as much as the whole business [...]
bermudashorts
25/1/2018
16:47
Numis reiterates 300p target price today
mfhmfh
25/1/2018
16:43
yes strong update this morning.
bermudashorts
25/1/2018
14:50
- staircase, tighter spread
piedro
23/1/2018
14:38
Unless they're some sort of transfer, would have expected a postitve move in share price with buys at that level.
bermudashorts
23/1/2018
13:41
We should get an RNS 1,356,372 of 42,680,813 ord shares = 3.18% {x2 = 6.38%}
piedro
23/1/2018
12:03
2 big buys/huge volume today.
mfhmfh
17/1/2018
13:52
Anybody know when to expect a trading update ?
nchanning
08/1/2018
15:39
FWIW ... Equity Development Ergomed plc 2018 – creating further value https://tinyurl.com/y9l8a45e
piedro
02/1/2018
16:49
Timbo/anyone still here? Any thoughts on replacement of Dr Dan Weng as CEO? He didn't last very long!
bermudashorts
12/12/2017
09:52
https://www.investegate.co.uk/ergomed-plc--ergo-/rns/co-dev-partnership-with-allergy-therapeutics/201712120700040254Z/
amchw
01/11/2017
18:08
Thanks - will be interesting not to follow the development of PeproStat.
bermudashorts
01/11/2017
10:11
EQUITY DEVELOPMENT EQUITY DEVELOPMENT CHAMPIONING GROWTH COMPANIES Ergomed : Positive PeproStat Data Symbol ERGO Listing AIM Share Price 210p Market Cap £89.6m Sector Healthcare Published 01/11/17 Analyst Elizabeth Klein Recently announced results from the phase II clinical trial of PeproStat were positive. As a result, the probability of PeproStat reaching the market increased from around a third to around two-thirds. This adds £12.7m to the valuation of this programme. As expected the shares saw strong performance on the back of the positive data. There remains significant upside to the bottom end of our 276p-401p valuation. Ergomed acquired Haemostatix in May 2016 for £28m (an initial £8.0m upfront, with the remainder in success-based milestone payments). Haemostatix had developed a new approach to controlling bleeding using a peptide that binds to fibrinogen, targeting a surgical market valued at c. US$2.5bn, growing at c. 6.2% pa. The phase II trial consisted of 169 patients treated (162 evaluable) at 16 sites in five European countries. PeproStat was shown to be clinically and significantly superior to standard of care across three surgery types. The mean time to Haemostasis was reduced by 1.55 minutes for PeproStat vs. standard of care, and favourable by investigator opinion (80.9% surgeons rated PeproStat (blinded) as good to excellent in controlling bleeding vs 59.6% for standard of care). The first commercial deal for a Haemsotatix product was signed late September with a South Korean company, Boryung Pharmaceutical Co. Ergomed will receive an upfront payment and a series of milestone payments as well as a double-digit share of all future product sales in this territory. Further PeproStat deals, along with the start of the next trial in H2 2018 and initial ReadyFlow data, should feature in the news flow over the next 12-18 months, along with further acquisitions to boost the profitability of the Services business. The bottom of the 276p - 401p per share valuation is based on the more conservative “Services-only” sales forecast, discounting completely the potential upside from Development projects. The top of the range adds in these projects with the Haeomstatix programme now making up 60% of the Development valuation.
douglas fir
24/10/2017
19:17
hxxps://youtu.be/FFCT_F8zDpQ
mfhmfh
23/10/2017
20:05
Interview with Andrew Mackie here:- hxxps://www.goinpharma.com/en/new-antibiotic-therapies-what-future/ Link to more detailed presentation of Peprostat clinical trial results here:- hxxp://www.ergomedplc.com/investor-relations/reports-presentations
bermudashorts
23/10/2017
17:17
Good to see Singers sum of the parts valuation raised to 367p -a long way to go yet. When further licensing deals are announced the shares are likely to strengthen further as the scale of the opportunity becomes more apparent
buffetteer
23/10/2017
10:09
HTTP://labiotech.eu/ergomed-peprostat-surgery/
mirabeau
23/10/2017
10:07
Nice write up here from Labiotech hxxps://labiotech.eu/ergomed-peprostat-surgery/
bermudashorts
23/10/2017
08:40
Sounds like they will licence out the product prior to Phase 3 so will lose control of the timing.
jamtomorrow2
23/10/2017
08:35
Piedro Yes, maybe, but I'm now wondering if there may some sort of sliding scale as suggested by BB. But if not, then it may be in their interest to commence the study prior to conducting a placing of that size.
timbo003
Chat Pages: 10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180223 14:58:43